Mouse anti-Human Collagen Type IV, 7S Domain (Arresten, ASLN, ATS, CA54, Canstatin, COL4A1, COL4A2, DKFZp686I14213, FLJ22259, Goodpasture antigen) Collagen Alpha 1(IV) Chain, Collagen Alpha 2(IV) Chain, Collagen IV Alpha 1 Polypeptide, Collagen IV Alpha 2 Polypeptide, Collagen of Basement Membrane Alpha 1 Chain, Colla

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 2; NC_000002.11 (228029281..228179508). Location: 2q36-q37

Monoclonal

IgG1

2Q644

Mouse

Recognizes human Collagen Type IV. Does not react with rat

Purified immunoglobulin

Supplied as a liquid in 0.1M sodium phosphate, pH 7.0, 2% BSA (protease-free).

2 mg/ml (lot specific)

May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Small volumes of anti-COL4A3 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Applications: Western blot: 2-10ug/ml. Detects human type IV collagen from human placental tissues giving a band at approximately 92kD.

Antibodies; Abs to Collagen

Western Blot (WB), Immunohistochemistry (IHC)
Other applications have not been tested

Western Blot:2-10ug/ml Detects human type IV collagen from human placental tissues giving a band at approximately 92kD.
Immunohistochemistry (Frozen):1-10ug/ml
Immunohistochemistry (Paraffin): 1-10ug/ml

Optimal dilutions to be determined by the researcher

collagen, type IV, alpha 3 (Goodpasture antigen)

collagen alpha-3(IV) chain; collagen alpha-3(IV) chain; tumstatin; collagen IV, alpha-3 polypeptide

Collagen alpha-3(IV) chain

CO4A3_HUMAN

Type IV collagen, the major structural component of basement membranes, is a multimeric protein composed of 3 alpha subunits. These subunits are encoded by 6 different genes, alpha 1 through alpha 6, each of which can form a triple helix structure with 2 other subunits to form type IV collagen. This gene encodes alpha 3. In the Goodpasture syndrome, autoantibodies bind to the collagen molecules in the basement membranes of alveoli and glomeruli. The epitopes that elicit these autoantibodies are localized largely to the non-collagenous C-terminal domain of the protein. A specific kinase phosphorylates amino acids in this same C-terminal region and the expression of this kinase is upregulated during pathogenesis. This gene is also linked to an autosomal recessive form of Alport syndrome. The mutations contributing to this syndrome are also located within the exons that encode this C-terminal region. Like the other members of the type IV collagen gene family, this gene is organized in a head-to-head conformation with another type IV collagen gene so that each gene pair shares a common promoter. [provided by RefSeq, Jun 2010]

COL4A3: Type IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen. Autoantibodies against the NC1 domain of alpha 3(IV) are found in Goodpasture syndrome, an autoimmune disease of lung and kidney. Defects in COL4A3 are a cause of Alport syndrome autosomal recessive (APSAR). APSAR is characterized by progressive glomerulonephritis, glomerular basement membrane defects, renal failure, sensorineural deafness and specific eye abnormalities (lenticonous and macular flecks). The disorder shows considerable heterogeneity in that families differ in the age of end-stage renal disease and the occurrence of deafness. Defects in COL4A3 are a cause of benign familial hematuria (BFH); also known as thin basement membrane nephropathy. BFH is characterized by persistent hematuria, an electron microscopically detectable thin glomerular basement membrane (GBM) and an autosomal dominant mode of inheritance. Renal function remains normal. In children, differentiation between BFH and AS can be difficult, because both disorders are manifested by persistent hematuria and thin GBM at that age. Defects in COL4A3 are a cause of Alport syndrome autosomal dominant (APSAD). Alport syndrome is characterized by progressive glomerulonephritis, glomerular basement membrane defects, renal failure, sensorineural deafness and specific eye abnormalities (lenticonous and macular flecks). The disorder shows considerable heterogeneity in that families differ in the age of end-stage renal disease and the occurrence of deafness. Belongs to the type IV collagen family. 5 isoforms of the human protein are produced by alternative splicing.

Protein type: Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 2q36-q37

Cellular Component: endoplasmic reticulum lumen; collagen type IV; extracellular region; basement membrane

Molecular Function: metalloendopeptidase inhibitor activity; integrin binding; protein binding; extracellular matrix structural constituent; structural molecule activity

Biological Process: caspase activation; extracellular matrix disassembly; negative regulation of cell proliferation; collagen catabolic process; axon guidance; cell proliferation; extracellular matrix organization and biogenesis; negative regulation of angiogenesis; sensory perception of sound; cell surface receptor linked signal transduction; blood circulation; glomerular basement membrane development; cell adhesion

Disease: Hematuria, Benign Familial; Alport Syndrome, Autosomal Dominant; Alport Syndrome, Autosomal Recessive

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.